Pado pcDNA3.1 Citations (17)

Originally described in: Pado, a fluorescent protein with proton channel activity can optically monitor membrane potential, intracellular pH, and map gap junctions.
Kang BE, Baker BJ Sci Rep. 2016 Apr 4;6:23865. doi: 10.1038/srep23865. PubMed Journal

---

Articles Citing Pado pcDNA3.1

Articles
Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1. Ge J, Wang J, Xiong F, Jiang X, Zhu K, Wang Y, Mo Y, Gong Z, Zhang S, He Y, Li X, Shi L, Guo C, Wang F, Zhou M, Xiang B, Li Y, Li G, Xiong W, Zeng Z. Cancer Res. 2021 Oct 1;81(19):5074-5088. doi: 10.1158/0008-5472.CAN-20-4321. Epub 2021 Jul 28. PubMed
High glucose-mediated VPS26a down-regulation dysregulates neuronal amyloid precursor protein processing and tau phosphorylation. Chae CW, Choi GE, Jung YH, Lim JR, Cho JH, Yoon JH, Han HJ. Br J Pharmacol. 2022 Aug;179(15):3934-3950. doi: 10.1111/bph.15836. Epub 2022 Apr 5. PubMed
Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer. Manouchehri JM, Datta J, Willingham N, Wesolowski R, Stover D, Ganju RK, Carson WE, Ramaswamy B, Cherian MA. Front Oncol. 2022 Apr 20;12:855032. doi: 10.3389/fonc.2022.855032. eCollection 2022. PubMed
NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer. O'Neill KI, Kuo LW, Williams MM, Lind H, Crump LS, Hammond NG, Spoelstra NS, Caino MC, Richer JK. Cancers (Basel). 2022 Jul 21;14(14):3543. doi: 10.3390/cancers14143543. PubMed
LncRNA CARMN inhibits cervical cancer cell growth via the miR-92a-3p/BTG2/Wnt/beta-catenin axis. Wang L, Zhao H, Fang Y, Yuan B, Guo Y, Wang W. Physiol Genomics. 2023 Jan 1;55(1):1-15. doi: 10.1152/physiolgenomics.00088.2022. Epub 2022 Oct 31. PubMed
Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours. Watanabe Y, Tsukahara T, Murata K, Hamada S, Kubo T, Kanaseki T, Hirohashi Y, Emori M, Teramoto A, Nakatsugawa M, Yamashita T, Torigoe T. Br J Cancer. 2023 Mar;128(5):886-895. doi: 10.1038/s41416-022-02100-1. Epub 2022 Dec 16. PubMed
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance. Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. Cancer Cell. 2023 Feb 13;41(2):340-355.e6. doi: 10.1016/j.ccell.2023.01.007. PubMed
Sleeping Beauty transposon system for GDNF overexpression of entrapped stem cells in fibrin hydrogel in a rat model of Parkinson's disease. Stahn L, Rasinska J, Dehne T, Schreyer S, Hakus A, Gossen M, Steiner B, Hemmati-Sadeghi S. Drug Deliv Transl Res. 2023 Jun;13(6):1745-1765. doi: 10.1007/s13346-023-01289-9. Epub 2023 Feb 28. PubMed
Breast metastatic tumors in lung can be substituted by lung-derived malignant cells transformed by alternative splicing H19 lncRNA. Xu JB, Cao J, Xia J, Zhu Y, He Y, Cao MG, Fang BM, Thiery JP, Zhou W. Breast Cancer Res. 2023 May 30;25(1):59. doi: 10.1186/s13058-023-01662-z. PubMed
Sulfatase 2 Inhibition Sensitizes Triple-Negative Breast Cancer Cells to Chemotherapy Through Augmentation of Extracellular ATP. Manouchehri JM, Marcho L, Cherian MA. bioRxiv [Preprint]. 2023 Sep 17:2023.09.15.557965. doi: 10.1101/2023.09.15.557965. PubMed
Exosomal lncRNA NEAT1 Inhibits NK-Cell Activity to Promote Multiple Myeloma Cell Immune Escape via an EZH2/PBX1 Axis. Wang QM, Lian GY, Sheng SM, Xu J, Ye LL, Min C, Guo SF. Mol Cancer Res. 2024 Feb 1;22(2):125-136. doi: 10.1158/1541-7786.MCR-23-0282. PubMed
TNFRSF19 within the 13q12.12 Risk Locus Functions as a Lung Cancer Suppressor by Binding Wnt3a to Inhibit Wnt/beta-Catenin Signaling. Zuo X, Wang X, Ma T, Chen S, Cao P, Cheng H, Yang N, Han X, Gao W, Liu X, Sun Y. Mol Cancer Res. 2024 Mar 1;22(3):227-239. doi: 10.1158/1541-7786.MCR-23-0109. PubMed
Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3beta/TCF7/MMP9 pathway and synergies with capecitabine. Dai X, Chen W, Qiao Y, Chen X, Chen Y, Zhang K, Zhang Q, Duan X, Li X, Zhao J, Tian F, Liu K, Dong Z, Lu J. Cancer Lett. 2024 Feb 1;582:216596. doi: 10.1016/j.canlet.2023.216596. Epub 2023 Dec 13. PubMed
Microenvironment-induced CREPT expression by cancer-derived small extracellular vesicles primes field cancerization. Lin Y, Jiang H, Li J, Ren F, Wang Y, Qiu Y, Li J, Li M, Wang Y, Yang L, Song Y, Jia H, Zhai W, Kuang Y, Yu H, Zhu W, Liu S, Morii E, Ensinger C, David C, Zheng H, Ji J, Wang H, Chang Z. Theranostics. 2024 Jan 1;14(2):662-680. doi: 10.7150/thno.87344. eCollection 2024. PubMed
Clinically-observed FOXA1 mutations upregulate SEMA3C through transcriptional derepression in prostate cancer. Tam KJ, Liu L, Hsing M, Dalal K, Thaper D, McConeghy B, Yenki P, Bhasin S, Peacock JW, Wang Y, Cherkasov A, Rennie PS, Gleave ME, Ong CJ. Sci Rep. 2024 Mar 25;14(1):7082. doi: 10.1038/s41598-024-57854-w. PubMed
The role of heparan sulfate in enhancing the chemotherapeutic response in triple-negative breast cancer. Manouchehri JM, Datta J, Marcho LM, Reardon JJ, Stover D, Wesolowski R, Borate U, Cheng TD, Schnell PM, Ramaswamy B, Sizemore GM, Rubinstein MP, Cherian MA. Breast Cancer Res. 2024 Nov 6;26(1):153. doi: 10.1186/s13058-024-01906-6. PubMed
Tp53 determines the spatial dynamics of M1/M2 tumor-associated macrophages and M1-driven tumoricidal effects. Hsiao YJ, Hsieh MS, Chang GC, Hsu YC, Wang CY, Chen YM, Chen YL, Yang PC, Yu SL. Cell Death Dis. 2025 Jan 22;16(1):38. doi: 10.1038/s41419-025-07346-0. PubMed

If you have published an article using this material, please email us at to have your article added to this page.